How can the EU’s pharmaceutical legislation help tackle current challenges, including medicine shortages and antimicrobial resistance, across Europe? We put the question to Rainer Becker, Director for Medical Products and Innovation at DG SANTE.
A crackdown on fake medicines and medical devices by the Medicines and Healthcare products Regulatory Agency (MHRA) has netted a haul of more than 1 million doses worth in excess of £2 million
The National Academy of Sciences (PNAS) has published new research which reveals that Huntington's Disease may take affect in people much earlier on in life than originally expected and that a new drug may be paramount in controlling the disease.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision synergy Group explains the role of cutting-edge technology in the personalised nanomedicine space, with a special focus on 3D printing nanomedicines.
The Office for National Statistics has today revealed that the number of drug-related deaths in England and Wales is the highest since records began, with opiate-based prescription painkiller Codeine claiming 20% more lives this year compared to last
During the Hybrid Summit 2018 in Bangkok, software providers HEX Innovation launched a blockchain platform enabled service to be used by the medical sectors.
The gap in the long process of progressing a novel scientific insight into a new medicine is often called “the valley of death”. Read below to understand how the strategic alliance between University of Oxford and Novo Nordisk is aiming to combat type 2 diabetes by bridging this gap.
Professor John Wilding from the University of Liverpool charts priorities for improving patient care in the UK when it comes to the prevalent condition, Type 2 diabetes
Cecilia Van Cauwenberghe from Frost & Sullivan shares her expertise on the world of nanomedicines, with a special focus on depicting human health risks hindering clinical translation.
Cecilia Van Cauwenberghe from the TechVision Group at Frost & Sullivan provides a detailed analysis of the present concerns and foreseen opportunities around muscular dystrophy (MD)
Prof Colin J Suckling OBE DSc FRSE, research professor of chemistry at the University of Strathclyde’s Department of Pure & Applied Chemistry shares his views on the challenge of commercialisation when it comes to research into medicinal chemistry
Bradley Moore, CEO of GCAC discusses how artificial intelligence and blockchain (trusted data) solve the paradox of limited medical cannabis data and anecdotal user information
Writer, medical cannabis patient, a grower and budtender for GrassRoots Medicinal in Squamish, Caleb McMillan, provides his thoughts on cannabis developments in North America today
Board Member for Canadians for Fair Access to Medical Marijuana (CFAMM), Peter Thurley, shares his views on medical cannabis advocacy and education issues
